logo
1 No-Brainer Artificial Intelligence (AI) Stock to Buy With $190 and Hold for the Long Term

1 No-Brainer Artificial Intelligence (AI) Stock to Buy With $190 and Hold for the Long Term

Yahoo24-05-2025

Palo Alto Networks is quickly becoming a leader in artificial intelligence (AI)-powered cybersecurity.
The company is forecasting nearly 200% growth in its AI revenue over the next five years, which could drive significant upside in its stock.
Palo Alto stock currently trades at a steep discount to its main rival, CrowdStrike, which might spell an opportunity for investors.
10 stocks we like better than Palo Alto Networks ›
Palo Alto Networks (NASDAQ: PANW) is the world's biggest cybersecurity vendor, but it isn't resting on its success. The company continues to expand its portfolio of products and services, leaning on innovations like artificial intelligence (AI) to deliver the most advanced protection to date.
Palo Alto recently reported its financial results for its fiscal 2025 third quarter (ended April 30), and it delivered accelerated revenue growth thanks to a combination of its AI products, and a shift in its business strategy which is starting to pay off. Here's why investors with a spare $190 (money they don't need for immediate expenses) might want to buy a single share of Palo Alto and hold it for the long term.
Palo Alto offers dozens of cybersecurity products spread across three primary platforms: Cloud security, network security, and security operations. The company is weaving AI into as many of those products as possible to automate threat detection and incident response processes, because speed is everything when it comes to neutralizing a threat.
The Cortex XSIAM security operations solution is a shining example of this strategy. Human-led cybersecurity processes are no longer sufficient to deal with the growing volume of modern-day threats, so XSIAM allows large organizations to defer more of those workloads to AI and automation.
Around 60% of companies using XSIAM have reduced their median time to remediate (MTTR) incidents to under 10 minutes, from two or three days previously. That means fewer cyber threats are slipping through the cracks, which significantly reduces the risk of a major breach. During the fiscal 2025 third quarter, XSIAM's annual recurring revenue (ARR) surged by 200% year over year. The platform was launched just two and a half years ago, and it's already approaching $1 billion in bookings on a trailing 12-month basis.
But Palo Alto is also trying to protect businesses that are using AI. The company recently launched a new platform called Prisma AIRS, which secures sensitive data when it's plugged into AI models from third-party developers like OpenAI, and scans external AI applications for vulnerabilities to ensure they are safe to use. This is a new product segment for Palo Alto, but the company estimates it has an eye-popping $15 billion addressable market already.
Palo Alto generated $2.3 billion in total revenue during the fiscal 2025 third quarter. It represented a 15% increase from the year-ago period, which marked an acceleration from the 14% growth the company delivered in the second quarter three months earlier.
The strong result was partly driven by Palo Alto's next-generation security (NGS) segment, which is where the company accounts for revenue from its AI products. NGS ARR soared by 34% to a record $5.1 billion during the quarter.
But "platformization" was also a big contributor to the third-quarter result. The cybersecurity industry has a history of fragmentation, meaning different vendors specialized in specific products, so businesses had to piece their security stack together from multiple providers. Palo Alto is now focusing on platformization, which involves becoming the one-stop vendor that fulfills all of a customer's cybersecurity needs.
Some customers might need all three of Palo Alto's platforms, whereas others might only need cloud security, but platforming them enables the company to capture more of their spending over the long term. During the third quarter, 1,250 of Palo Alto's top 5,000 customers were officially platformed, which was up nearly 39% year over year.
Products like Cortex XSIAM are a key driver of platformizations, because they require an "all-in" approach from the customer. That's because XSIAM is designed to take over the entire security operations center, so it consolidates many legacy cybersecurity tools from other vendors into one single platform, basically making them redundant.
Despite Palo Alto's leadership position in the cybersecurity industry, its stock actually trades at a steep discount to one of its main rivals, CrowdStrike (NASDAQ: CRWD). Its price-to-sales (P/S) ratio is 14.9 as of this writing, which is 45% below CrowdStrike's P/S ratio of 27.3:
Growth is one of the reasons for the disparity. CrowdStrike will report its latest quarterly financial results on June 3, and it is forecast to have grown its revenue by 20%, which is a faster rate than Palo Alto's 15%. However, Palo Alto's NGS ARR of $5.1 billion alone is higher than CrowdStrike's total annual revenue, and remember, it soared by 34%. Therefore, I think Palo Alto stock deserves to close the valuation gap to CrowdStrike.
Plus, the company is aiming to nearly triple its NGS ARR to $15 billion by 2030, with help from as many as 3,500 platformizations, so there is plenty of growth still in the tank.
Moreover, Palo Alto values its addressable market for Cortex XSIAM alone at $40 billion, which is 40 times higher than the product's current annual bookings. That's in addition to the $15 billion opportunity in Prisma AIRS. In other words, AI has extended Palo Alto's potential growth runway significantly.
As a result, I think Palo Alto stock might be a no-brainer buy right now, especially for investors who can hold it for the next five years (or more) as NGS revenue ramps up.
Before you buy stock in Palo Alto Networks, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palo Alto Networks wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $639,271!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $804,688!*
Now, it's worth noting Stock Advisor's total average return is 957% — a market-crushing outperformance compared to 167% for the S&P 500. Don't miss out on the latest top 10 list, available when you join .
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Anthony Di Pizio has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends CrowdStrike. The Motley Fool recommends Palo Alto Networks. The Motley Fool has a disclosure policy.
1 No-Brainer Artificial Intelligence (AI) Stock to Buy With $190 and Hold for the Long Term was originally published by The Motley Fool

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Time To Buy AMZN Stock?
Time To Buy AMZN Stock?

Forbes

time15 minutes ago

  • Forbes

Time To Buy AMZN Stock?

A view of the Amazon warehouse in Pawlikowice, Poland on May 29, 2025. (Photo by Jakub ... More Porzycki/NurPhoto via Getty Images) Amazon (NASDAQ:AMZN) is really leaning into AI, recently announcing a massive $10 billion investment in new data centers in North Carolina. Like Google and Microsoft, Amazon has been a major player in the AI boom, spending a whopping $222 billion on capital expenditures since 2022. The stock has seen a nice jump lately, climbing 24% from around $167 on April 21 to $208 now. This rally seems to be fueled by the broader market's positive reaction to new trade deals and a pause on reciprocal tariffs between the U.S. and China. The probability of the U.S. economy going into a recession this year has also come down from 60% earlier to 40% now, according to J.P. Morgan Research. Given the change in overall market sentiment, you might be wondering if Amazon is still a smart investment after its recent climb. We believe it is. Even with the recent rally, Amazon shows strong operational growth and solid financial health, and its stock isn't overpriced. Our analysis dives deep into Amazon's investment potential by looking at its current valuation compared to its recent operating performance and overall financial health. We've assessed Amazon across key areas like Growth, Profitability, Financial Stability, and Downturn Resilience. Our findings show that Amazon has a strong operating performance and financial condition. That said, if you seek upside with lower volatility than individual stocks, the Trefis High Quality portfolio presents an alternative - having outperformed the S&P 500 and generated returns exceeding 91% since its inception. Separately, see – RGTI Stock: What's Next After An 1,100% Rally? When we look at AMZN stock against the broader market, it seems pretty reasonable. Amazon's price-to-sales ratio is 3.4 times, which is pretty close to the S&P 500's 3.0 times. Its price-to-earnings (P/E) ratio of 33.3 times is higher than the market's 26.4 times, but its price-to-free cash flow ratio is 19.3 times, which is slightly better than the S&P 500's 20.5 times. This means Amazon is doing a good job generating cash compared to its price. Check out our dashboard on Amazon's Valuation Ratios for more details. This moderate valuation suggests that Amazon isn't really getting a premium for its growth potential right now. It's likely that those high capital expenditures we mentioned earlier have made some investors a bit nervous. While that higher P/E ratio signals that the market expects Amazon's earnings to keep growing, it also means the stock could be vulnerable if that growth slows down. However, it's worth noting that this 33x P/E is actually lower than Amazon's average P/E of 46x over the past two years. Amazon's revenue just keeps climbing, showing how good they are at expanding across all their different businesses. Over the last three years, their annual revenue has grown by an average of 11%, much better than the S&P 500's 5.5%. This strong performance continued in the past year, with revenues jumping 10.1% from $591 billion to $650 billion. Looking at their most recent quarterly results, things are still looking good. Revenues grew 8.6% to $156 billion compared to $143 billion in the same period last year. This consistent growth, whether we're looking at annual or quarterly numbers, really highlights how Amazon's diverse business model keeps them expanding, even as they get bigger and bigger. While Amazon's revenues are trending higher, its profitability tells a slightly different story, and it might explain why some investors are a bit hesitant. For instance, their operating margin is 11.0%, which is a bit lower than the S&P 500's average of 13.2%. This suggests they're facing some challenges in turning all that revenue into efficient operations. Similarly, Amazon's net income margin of 10.1% also lags behind the broader market's 11.6% average. However, Amazon's operating cash flow margin is 17.5%, actually beating the S&P 500's 14.9%. This means they're doing a great job at generating cash, even if their accounting profits seem lower. This difference often comes down to Amazon's huge investments in growth and infrastructure. These investments might hit the company's short-term profit margins, but they're setting it up for bigger growth down the road. Amazon's balance sheet is incredibly strong, giving them a really solid base to handle any economic bumps in the road. The company's debt-to-equity ratio is super low at just 6.1%, which is way better than the S&P 500's average of 19.9%. This conservative approach means Amazon has tons of financial wiggle room for big investments. They're also sitting on a good amount of cash. Cash and cash equivalents make up 14.7% of their total assets, slightly more than the broader market's 13.8%. With $95 billion in cash and $643 billion in total assets, Amazon has serious resources to chase new growth opportunities and ride out any tough times. Looking back at how Amazon's stock performed during past market downturns gives us some good insights. It shows they can be pretty resilient, but also quite volatile. During the COVID-19 pandemic in 2020, Amazon actually held up pretty well. Their stock only dropped 22.7% compared to the S&P 500's 33.9% plunge, and it bounced back to pre-crisis levels in just two months. However, things were a bit different during the 2022 inflation shock. Amazon's stock took a bigger hit, falling 56.1% while the market dropped 25.4%. It took almost two years for the stock to fully recover, which just goes to show how growth stocks can feel more pain when interest rates go up and valuations get squeezed. The 2008 financial crisis presented similar challenges, with Amazon declining 65.3% against the market's 56.8% drop, though it also recovered within two years. These patterns suggest that while Amazon tends to swing more during severe market stress, it typically has the underlying strength to bounce back over time. We believe Amazon is an attractive investment right now. It offers a good valuation combined with incredibly strong fundamentals and a solid financial position. The company is delivering double-digit revenue growth and boasts a fortress-like balance sheet. These strengths outweigh any minor concerns about profitability. Notably, Amazon's AWS segment is far more profitable, boasting estimated EBITDA margins of around 45% last year, than its other businesses, which have EBITDA margins under 15%. With AWS's contribution to the company's overall sales on the rise—up from 12% in 2021 to 17% last year—the overall profitability will also improve. Furthermore, with a proven ability to recover from downturns, Amazon provides an excellent entry point into the long-term growth trends of the ongoing AI boom. It's a strong addition for growth-oriented portfolios. Not too happy about the volatile nature of AMZN stock? The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming the S&P 500 over the last 4-year period. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride as evident in HQ Portfolio performance metrics.

LQR House Announces Upcoming Marketing Partnerships With Saltwater Woody
LQR House Announces Upcoming Marketing Partnerships With Saltwater Woody

Indianapolis Star

time28 minutes ago

  • Indianapolis Star

LQR House Announces Upcoming Marketing Partnerships With Saltwater Woody

MIAMI BEACH, FL / ACCESS Newswire LQR House Inc. (the 'Company' or 'LQR House') (NASDAQ:YHC), a niche ecommerce platform specializing in the spirits and beverage industry, is proud to announce a new marketing services agreement with Saltwater Woody, an American rum brand known for its bold flavor and production process, starting in the middle of June 2025. Under the agreement, Saltwater Woody will engage LQR House to execute a strategic marketing campaign aimed at building brand awareness and driving sales on The campaign will spotlight Saltwater Woody's full portfolio of rums, including Original American Rum, Real Coconut, Real Grapefruit, Real Lemon, and Grilled Pineapple. According to its representatives, crafted in small batches and infused with real fruit juice and a splash of saltwater, Saltwater Woody stands apart in a saturated category. It's a brand built on authenticity-no artificial flavors, just real ingredients and a refreshing twist that turns every sip into something memorable. 'At LQR House, we're always on the hunt for brands that do things differently,' said Sean Dollinger, CEO of LQR House. 'In today's world, where everyone's a content creator, we believe brands need to give creators something fresh and exciting to work with-something that cuts through the noise. We believe that Saltwater Woody nails that. From its clean ingredients to its innovative saltwater infusion, in our view, it's exactly the kind of product that creators can get behind and fans can get excited about.' This collaboration is part of LQR House's broader mission to elevate craft and emerging brands by offering customized marketing solutions, including influencer campaigns, SEO optimization, and e-commerce support. John Ormiston, Partner at Twenty20 Beverages, who facilitated the partnership, added: 'At Twenty20, we love aligning with brands that bring something genuinely special to the table-and Saltwater Woody does just that. We're thrilled to see this tailored campaign come to life and are confident it will unlock new opportunities for one of our most exciting brands in the portfolio.' About LQR House Inc. LQR House intends to become a prominent force in the wine and spirits e-commerce sector, epitomized by its flagship alcohol marketplace, This platform seamlessly delivers a diverse range of emerging, premium, and luxury spirits, wines, and champagnes from esteemed retail partners like Country Wine & Spirits. Functioning as a technology-driven hub, LQR House utilizes software, data analytics, and artificial intelligence to elevate consumer experience. stands out as the go-to destination for modern, convenience-oriented shoppers, providing a curated selection of alcohol products delivered to homes across the United States. Beyond its role in an e-commerce sector, LQR House is a marketing agency with a specialized focus on the alcohol industry. The Company measures campaign success by directly correlating it with sales on demonstrating a return on investment. Backed by an influential network of around 460 figures in the alcohol space, LQR House strategically drives traffic to enhancing brand visibility. LQR House intends to disrupt the traditional landscape of the alcohol industry, driven by its dedication to providing an unparalleled online purchasing experience and delivering tailored marketing solutions. Forward-Looking Statements Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Shareholders can identify these forward-looking statements by words or phrases such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'is/are likely to,' 'potential,' 'continue' or other similar expressions. Forward-looking statements contained in this press release are made only as of the date of this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions, and other factors discussed in the 'Risk Factors' section of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the United States Securities and Exchange Commission (the 'SEC'). You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the headings 'Risk Factors'. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results described in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and in other reports and documents that the Company files from time to time with the SEC. Additional factors are discussed in the Company's filings with the SEC, which are available for review at References and links to websites have been provided as a convenience, and the information contained on such websites has not been incorporated by reference into this press release. Investor and Media Contact: info@ SOURCE: LQR House

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025
Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Yahoo

time32 minutes ago

  • Yahoo

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

Emerging Biomarkers in the Clinical Development of Epilepsy Medicines and OV329 Program Highlights NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need, will host an investor and media event on Thursday, June 12, 2025, on the topic of applying Biomarkers in Epilepsy, including their strategic use to demonstrate the pharmacodynamic activity of the Company's OV329 clinical development program. World-leading expert, Dr. Alexander Rotenberg will join company management to discuss the emerging use of a wide range of biomarkers for the study of anti-seizure medicines. The event will take place at Ovid's headquarters in New York's Hudson Yards from 9:30 to 10:30 am ET and will be webcast simultaneously. Sophisticated imaging and radiological tools are increasingly enabling medicines developers to leverage biomarkers earlier in clinical development to identify signals of biological target engagement and pharmacodynamic activity. Discussion will focus on how these tools drive evidence informed approaches in drug development and provide insight into potential clinical outcomes. Ovid management will describe the exploratory biomarkers in use to measure its next-generation GABA-aminotransferase (GABA-AT) inhibitor program, OV329, which is anticipated to have a topline readout in Q3 2025. Keynote speaker: Leading pediatric neurologist and epileptologist Alexander Rotenberg, M.D., Ph.D. Professor of Neurology at Boston Children's Hospital and Harvard Medical School, and Director of the Epilepsy Monitoring Unit at Boston Children's Hospital, and the Experimental Neurophysiology Core at F.M. Kirby Center of Neurobiology Unfortunately, nearly 40 percent of people living with epilepsy continue to experience seizures despite existing medicines. OV329 is a next-generation GABA-AT inhibitor, that was rationally designed to work differently from current medicines and may offer a novel approach for patients with treatment-resistant seizures. OV329 seeks to endogenously deliver optimal levels of GABA to reduce seizures and provide a preferable safety and tolerability profile relative to the first-generation, GABA-AT inhibitor, vigabatrin. OV329 is currently completing a Phase 1 study that is evaluating its effects on multiple pharmacodynamic biomarkers, safety, tolerability, and pharmacokinetics. Interested in attending or participating remotely: To register, please visit: Registration Link A live webcast of the presentation can be accessed through the Events & Presentations section of Ovid's website at About Ovid Therapeutics Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. Ovid is developing: OV329, a next-generation GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. For more information about these and other Ovid research programs, please visit Forward-Looking Statements This press release includes certain disclosures by Ovid that contain 'forward-looking statements' including, without limitation: statements regarding the expected timing of initiation, completion, and results and data of Ovid's clinical studies; the potential use and development of OV329, OV350, OV4071 and other compounds from Ovid's library of direct activators of KCC2; and other statements that are not historical fact. You can identify forward-looking statements because they contain words such as 'anticipates,' 'believes,' 'expects,' 'intends,' 'may,' 'plan,' 'potentially,' and 'will,' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid's current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid's ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its business strategy or unanticipated or greater than anticipated impacts or delays due to macroeconomic and geopolitical conditions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption 'Risk Factors' in Ovid's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ('SEC'), and in subsequent and future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law. Media and Investor Relations:Victoria Fort vfort@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store